Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Operations: 2019-2024

Historic Cash from Operations for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to $10.3 million.

  • Mirum Pharmaceuticals' Cash from Operations rose 896.01% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.7 million, marking a year-over-year increase of 3748.33%. This contributed to the annual value of $10.3 million for FY2024, which is 114.55% up from last year.
  • As of FY2024, Mirum Pharmaceuticals' Cash from Operations stood at $10.3 million, which was up 114.55% from -$70.9 million recorded in FY2023.
  • In the past 5 years, Mirum Pharmaceuticals' Cash from Operations registered a high of $10.3 million during FY2024, and its lowest value of -$132.8 million during FY2021.
  • Over the past 3 years, Mirum Pharmaceuticals' median Cash from Operations value was -$70.9 million (recorded in 2023), while the average stood at -$60.3 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Cash from Operations plummeted by 126.30% in 2020 and then spiked by 114.55% in 2024.
  • Mirum Pharmaceuticals' Cash from Operations (Yearly) stood at -$89.1 million in 2020, then crashed by 49.04% to -$132.8 million in 2021, then climbed by 9.51% to -$120.1 million in 2022, then surged by 40.95% to -$70.9 million in 2023, then spiked by 114.55% to $10.3 million in 2024.